{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:08:35Z","timestamp":1769044115773,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00296-019-04456-9","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T16:03:21Z","timestamp":1570637001000},"page":"791-798","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Tocilizumab-induced anaphylaxis in patients with adult-onset Still\u2019s disease and systemic juvenile idiopathic arthritis: a case-based review"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6813-4182","authenticated-orcid":false,"given":"Eun Hye","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6975-8627","authenticated-orcid":false,"given":"Eun Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6749-7598","authenticated-orcid":false,"given":"Kichul","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2609-3367","authenticated-orcid":false,"given":"Hyoun-Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,9]]},"reference":[{"key":"4456_CR1","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","volume":"13","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Seve P (2014) Adult-onset Still\u2019s disease. Autoimmun Rev 13:708\u2013722","journal-title":"Autoimmun Rev"},{"key":"4456_CR2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.berh.2008.08.006","volume":"22","author":"B Fautrel","year":"2008","unstructured":"Fautrel B (2008) Adult-onset Still disease. Best Pract Res Clin Rheumatol 22:773\u2013792","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"4456_CR3","doi-asserted-by":"publisher","first-page":"5860","DOI":"10.2174\/0929867325666180522085716","volume":"25","author":"D Poddighe","year":"2018","unstructured":"Poddighe D, Romano M, Gattinara M, Gerloni V (2018) Biologics for the treatment of juvenile idiopathic arthritis. Curr Med Chem 25:5860\u20135893","journal-title":"Curr Med Chem"},{"key":"4456_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.clim.2016.05.010","volume":"169","author":"N Inoue","year":"2016","unstructured":"Inoue N, Shimizu M, Tsunoda S, Kawano M, Matsumura M, Yachie A (2016) Cytokine profile in adult-onset Still\u2019s disease: comparison with systemic juvenile idiopathic arthritis. Clin Immunol 169:8\u201313","journal-title":"Clin Immunol"},{"key":"4456_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","volume":"14","author":"E Feist","year":"2018","unstructured":"Feist E, Mitrovic S, Fautrel B (2018) Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease. Nat Rev Rheumatol 14:603\u2013618","journal-title":"Nat Rev Rheumatol"},{"key":"4456_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2147\/PPA.S41433","volume":"7","author":"I Al-Shakarchi","year":"2013","unstructured":"Al-Shakarchi I, Gullick NJ, Scott DL (2013) Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review. Patient Prefer Adherence 7:653\u2013666","journal-title":"Patient Prefer Adherence"},{"key":"4456_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12969-018-0296-z","volume":"16","author":"JY Jung","year":"2018","unstructured":"Jung JY, Kim MY, Suh CH, Kim HA (2018) Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review. Pediatr Rheumatol Online J 16:79","journal-title":"Pediatr Rheumatol Online J"},{"key":"4456_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10067-012-2105-2","volume":"32","author":"H de Boysson","year":"2013","unstructured":"de Boysson H, Fevrier J, Nicolle A, Auzary C, Geffray L (2013) Tocilizumab in the treatment of the adult-onset Still\u2019s disease: current clinical evidence. Clin Rheumatol 32:141\u2013147","journal-title":"Clin Rheumatol"},{"key":"4456_CR9","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/art.38398","volume":"66","author":"F Ortiz-Sanjuan","year":"2014","unstructured":"Ortiz-Sanjuan F, Blanco R, Calvo-Rio V, Narvaez J, Rubio Romero E, Olive A et al (2014) Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still\u2019s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol 66:1659\u20131665","journal-title":"Arthritis Rheumatol"},{"key":"4456_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/acr.23277","volume":"70","author":"GS Schulert","year":"2018","unstructured":"Schulert GS, Minoia F, Bohnsack J, Cron RQ, Hashad S, Kon EPI et al (2018) Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 70:409\u2013419","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4456_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3109\/03009742.2015.1074279","volume":"45","author":"W Ye","year":"2016","unstructured":"Ye W, Fifield MC, Mayhew A, Nasser S, Ostor A (2016) Successful tocilizumab desensitization in an adult with juvenile idiopathic arthritis. Scand J Rheumatol 45:75\u201376","journal-title":"Scand J Rheumatol"},{"key":"4456_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4137\/CMAMD.S4864","volume":"3","author":"G Jones","year":"2010","unstructured":"Jones G, Ding C (2010) Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 3:81\u201389","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"},{"key":"4456_CR13","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1093\/rheumatology\/keu181","volume":"53","author":"V Rocchi","year":"2014","unstructured":"Rocchi V, Puxeddu I, Cataldo G, Del Corso I, Tavoni A et al (2014) Hypersensitivity reactions to tocilizumab: role of skin tests in diagnosis. Rheumatology (Oxford) 53:1527\u20131529","journal-title":"Rheumatology (Oxford)"},{"key":"4456_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1468-3083.2009.03437.x","volume":"24","author":"R Yoshiki","year":"2010","unstructured":"Yoshiki R, Nakamura M, Tokura Y (2010) Drug eruption induced by IL-6 receptor inhibitor tocilizumab. J Eur Acad Dermatol Venereol 24:495\u2013496","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4456_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1067\/mai.2002.126811","volume":"110","author":"SF Kemp","year":"2002","unstructured":"Kemp SF, Lockey RF (2002) Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol 110:341\u2013348","journal-title":"J Allergy Clin Immunol"},{"key":"4456_CR16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bcp.12110","volume":"76","author":"EA Sandilands","year":"2013","unstructured":"Sandilands EA, Crowe J, Cuthbert H, Jenkins PJ, Johnston NR, Eddleston M et al (2013) Histamine-induced vasodilatation in the human forearm vasculature. Br J Clin Pharmacol 76:699\u2013707","journal-title":"Br J Clin Pharmacol"},{"key":"4456_CR17","first-page":"134","volume":"57","author":"JH Salmon","year":"2018","unstructured":"Salmon JH, Perotin JM, Morel J, Drame M, Cantagrel A, Ziegler LE et al (2018) Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data. Rheumatology (Oxford) 57:134\u2013139","journal-title":"Rheumatology (Oxford)"},{"key":"4456_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/acr.22110","volume":"66","author":"A Ogata","year":"2014","unstructured":"Ogata A, Tanimura K, Sugimoto T, Inoue H, Urata Y, Matsubara T et al (2014) Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66:344\u2013354","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4456_CR19","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/cea.13142","volume":"48","author":"P Tetu","year":"2018","unstructured":"Tetu P, Hamelin A, Moguelet P, Barbaud A, Soria A (2018) Management of hypersensitivity reactions to tocilizumab. Clin Exp Allergy 48:749\u2013752","journal-title":"Clin Exp Allergy"},{"key":"4456_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","volume":"70","author":"J Pouchot","year":"1991","unstructured":"Pouchot J, Sampalis JS, Beaudet F, Carette S, Decary F, Salusinsky-Sternbach M et al (1991) Adult Still\u2019s disease: manifestations, disease course, and outcome in 62 patients. Medicine 70:118\u2013136","journal-title":"Medicine"},{"key":"4456_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M (2014) Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 73:95\u2013100","journal-title":"Ann Rheum Dis"},{"key":"4456_CR22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jaip.2014.04.015","volume":"2","author":"A Justet","year":"2014","unstructured":"Justet A, Neukirch C, Poubeau P, Arrault X, Borie R, Dombret MC et al (2014) Successful rapid tocilizumab desensitization in a patient with Still disease. J Allergy Clin Immunol Pract 2:631\u2013632","journal-title":"J Allergy Clin Immunol Pract"},{"key":"4456_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1546-0096-13-4","volume":"13","author":"MM Kostik","year":"2015","unstructured":"Kostik MM, Dubko MF, Masalova VV, Snegireva LS, Kornishina TL, Chikova IA et al (2015) Successful treatment with tocilizumab every 4\u00a0weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis. Pediatr Rheumatol Online J 13:4","journal-title":"Pediatr Rheumatol Online J"},{"key":"4456_CR24","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1136\/annrheumdis-2015-207818","volume":"75","author":"S Yokota","year":"2016","unstructured":"Yokota S, Itoh Y, Morio T, Origasa H, Sumitomo N, Tomobe M et al (2016) Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1\u00a0year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis 75:1654\u20131660","journal-title":"Ann Rheum Dis"},{"key":"4456_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.biologicals.2018.07.002","volume":"55","author":"T Erdogan","year":"2018","unstructured":"Erdogan T, Yasar Bilge NS, Kasifoglu T (2018) Successful slow tocilizumab desensitization in a patient with adult onset Still disease. Biologicals 55:17\u201318","journal-title":"Biologicals"},{"key":"4456_CR26","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/acr.23141","volume":"69","author":"H Yun","year":"2017","unstructured":"Yun H, Xie F, Beyl RN, Chen L, Lewis JD, Saag KG et al (2017) Risk of hypersensitivity to biologic agents among medicare patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 69:1526\u20131534","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4456_CR27","doi-asserted-by":"publisher","first-page":"436","DOI":"10.18176\/jiaci.0314","volume":"28","author":"M Cansever","year":"2018","unstructured":"Cansever M, Sahin N, Dursun I, Geyik C, Dusunsel R, Bektas Kut F et al (2018) Successful slow desensitization to tocilizumab in a 15-year-old patient. J Investig Allergol Clin Immunol 28:436\u2013438","journal-title":"J Investig Allergol Clin Immunol"},{"key":"4456_CR28","first-page":"335","volume":"36","author":"MM Kostik","year":"2018","unstructured":"Kostik MM, Isupova EA, Chikova IA, Dubko MF, Masalova VV, Snegireva LS et al (2018) Reasons for inactive disease and flare in systemic onset juvenile idiopathic arthritis patients during tocilizumab treatment. Clin Exp Rheumatol 36:335\u2013341","journal-title":"Clin Exp Rheumatol"},{"key":"4456_CR29","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1080\/14397595.2018.1457490","volume":"29","author":"R Yasuoka","year":"2019","unstructured":"Yasuoka R, Iwata N, Abe N, Kohagura T, Nakaseko H, Shimizu M et al (2019) Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis. Mod Rheumatol 29:324\u2013327","journal-title":"Mod Rheumatol"},{"key":"4456_CR30","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jaci.2009.10.060","volume":"125","author":"L Cox","year":"2010","unstructured":"Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G (2010) Speaking the same language: the world allergy organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 125:569\u2013574 (574 e561\u2013574 e567)","journal-title":"J Allergy Clin Immunol"},{"key":"4456_CR31","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/bja\/aew251","volume":"117","author":"MA Rose","year":"2016","unstructured":"Rose MA, Green SL, Crilly HM, Kolawole H (2016) Perioperative anaphylaxis grading system: \u2018making the grade\u2019. Br J Anaesth 117:551\u2013553","journal-title":"Br J Anaesth"},{"key":"4456_CR32","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). \nhttp:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\n\n. Accessed 5 July 2016"},{"key":"4456_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000362266","volume":"228","author":"N Palmou-Fontana","year":"2014","unstructured":"Palmou-Fontana N, Sanchez Gavino JA, McGonagle D, Garcia-Martinez E, de Onzono Iniguez, Martin L (2014) Tocilizumab-induced psoriasiform rash in rheumatoid arthritis. Dermatology 228:311\u2013313","journal-title":"Dermatology"},{"key":"4456_CR34","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/rheumatology\/keu008","volume":"53","author":"S Sakaue","year":"2014","unstructured":"Sakaue S, Sumitomo S, Kubo K, Fujio K, Yamamoto K (2014) Tocilizumab-induced leucocytoclastic vasculitis in a patient with rheumatoid arthritis. Rheumatology (Oxford) 53:1529\u20131530","journal-title":"Rheumatology (Oxford)"},{"key":"4456_CR35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jbspin.2014.04.004","volume":"82","author":"CP Wu","year":"2015","unstructured":"Wu CP, Hsieh CW, Chen DY, Lee BJ, Yang CS (2015) Tocilizumab-associated cutaneous reactive endotheliomatosis in a patient with rheumatoid arthritis. Jt Bone Spine 82:132\u2013134","journal-title":"Jt Bone Spine"},{"key":"4456_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3121\/cmr.2017.1364","volume":"16","author":"R Sehgal","year":"2018","unstructured":"Sehgal R, Stratman EJ, Cutlan JE (2018) Biologic agent-associated cutaneous adverse events: a single center experience. Clin Med Res 16:41\u201346","journal-title":"Clin Med Res"},{"key":"4456_CR37","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","volume":"77","author":"LJ Scott","year":"2017","unstructured":"Scott LJ (2017) Tocilizumab: a review in rheumatoid arthritis. Drugs 77:1865\u20131879","journal-title":"Drugs"},{"key":"4456_CR38","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1200\/JCO.1999.17.3.791","volume":"17","author":"JC Byrd","year":"1999","unstructured":"Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP et al (1999) Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17:791\u2013795","journal-title":"J Clin Oncol"},{"key":"4456_CR39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2332\/allergolint.55.105","volume":"55","author":"T Yoshimoto","year":"2016","unstructured":"Yoshimoto T, Nakanishi K (2016) Roles of IL-18 in basophils and mast cells. Allergol Int 55:105\u2013113","journal-title":"Allergol Int"},{"key":"4456_CR40","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3899\/jrheum.120079","volume":"39","author":"HA Kim","year":"2012","unstructured":"Kim HA, An JM, Nam JY, Jeon JY, Suh CH (2012) Serum S100A8\/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still\u2019s disease. J Rheumatol 39:1399\u20131406","journal-title":"J Rheumatol"},{"key":"4456_CR41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.clim.2015.06.005","volume":"160","author":"M Shimizu","year":"2015","unstructured":"Shimizu M, Nakagishi Y, Inoue N, Mizuta M, Ko G, Saikawa Y et al (2015) Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clin Immunol 160:277\u2013281","journal-title":"Clin Immunol"},{"key":"4456_CR42","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3899\/jrheum.130690","volume":"41","author":"S Yokota","year":"2014","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N et al (2014) Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol 41:759\u2013767","journal-title":"J Rheumatol"},{"key":"4456_CR43","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/rheumatology\/kez030","volume":"58","author":"MJH Doeleman","year":"2019","unstructured":"Doeleman MJH, van Maarseveen EM, Swart JF (2019) Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 58:1839\u20131849","journal-title":"Rheumatology (Oxford)"},{"key":"4456_CR44","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I et al (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2385\u20132395","journal-title":"N Engl J Med"},{"key":"4456_CR45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jaip.2014.12.006","volume":"3","author":"VR Galvao","year":"2015","unstructured":"Galvao VR, Castells MC (2015) Hypersensitivity to biological agents-updated diagnosis, management, and treatment. J Allergy Clin Immunol Pract 3:175\u2013185 (quiz 186)","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04456-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-019-04456-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04456-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T23:51:37Z","timestamp":1602114697000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-019-04456-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,9]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["4456"],"URL":"https:\/\/doi.org\/10.1007\/s00296-019-04456-9","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,9]]},"assertion":[{"value":"7 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was provided by the patients or the patients\u2019 legal guardian in an appropriate format.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}